We pioneered the first linac based intensity modulated total marrow irradiation (IMTMI) and demonstrated outcome benefits through clinical trials. We have recently published results of our last Phase I study which sought to prospectively determine the role of TMI in advanced AML patients who are receiving second or higher transplant. This study demonstrated that adding TMI to standard of care has the ability to substantially improve both 2 years OS (50%) and PSF (48%) compared to our historical outcome data of 23% and 18%, respectively. To date, we have treated over 150 patients, which is the largest patient cohort treated with this technique.

The lab is developing advanced adaptive workflows for oligometastatic patients for rapid, on-table plan development.

Our work has developed techniques for developing IMRT treatment plans for small animals, developing models of compensators to achieve the necessary fluence modulation suitable for rapid fabrication with 3D printing using metal loaded plastics.  This cutting edge approach enables a range of preclinical studies, of which our group has a specific interest in personalized radiation therapy plans developed using functional imaging to address local variations in tumor physiology and microenvironment, see our other work on oxygen guided radiation therapy.

We are developing and optimizing theranostic PSMA-targeted gold nanoparticle that act as a MR contrast agent as well as a radio-sensitizer. With collaborators we are designing, synthesizing, characterizing and optimizing the utility of the particles in vitro and then utilize them for MR-guided radiotherapy in mice. These studies will lay the groundwork for this technology to be used for other cancers that express PSMA

Oxygen Guided Radiation Therapy Guiding radiation therapy based on local tissue oxygen measurements is critically important as hypoxia (low oxygen) in the tumor microenvironment has been shown to be a strong indicator of increased cancer progression and tumor...